ES2195994T3 - Virus recombinante de la enfermedad de marek, procedimiento de preparacion de este; y vacuna que lo contiene. - Google Patents

Virus recombinante de la enfermedad de marek, procedimiento de preparacion de este; y vacuna que lo contiene.

Info

Publication number
ES2195994T3
ES2195994T3 ES92111588T ES92111588T ES2195994T3 ES 2195994 T3 ES2195994 T3 ES 2195994T3 ES 92111588 T ES92111588 T ES 92111588T ES 92111588 T ES92111588 T ES 92111588T ES 2195994 T3 ES2195994 T3 ES 2195994T3
Authority
ES
Spain
Prior art keywords
marek
disease
virus
gene
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92111588T
Other languages
English (en)
Inventor
Masashi Sakaguchi
Michitaka Yamamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemo Sero Therapeutic Research Institute Kaketsuken
Original Assignee
Chemo Sero Therapeutic Research Institute Kaketsuken
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Sero Therapeutic Research Institute Kaketsuken filed Critical Chemo Sero Therapeutic Research Institute Kaketsuken
Application granted granted Critical
Publication of ES2195994T3 publication Critical patent/ES2195994T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE PRESENTA UN VIRUS RECOMBINANTE DE LA ENFERMEDAD DE MAREK PRODUCIDO MEDIANTE LA MUTACION DEL VIRUS DE LA ENFERMEDAD DE MAREK CON UN PLASMIDO EN EL QUE DICHO PLASMIDO COMPRENDE (1) UN FRAGMENTO DE GEN DERIVADO DE LA REGION US DE LAS SECUENCIAS DE REPETICION INVERTIDA ADYACENTES A AMBOS EXTREMOS DE DICHA REGION US DEL GENOMA DEL VIRUS DE LA ENFERMEDAD DE MAREK Y (2) UNA CASSETTE DE EXPRESION DE UN GEN EXOGENO INCORPORADA DE DICHO FRAGMENTO DE GEN, DICHA CASSETTE COMPRENDE UN GEN EXOGENO UNIDO CORRIENTE ABAJO DE UN PROMOTOR DERIVADO DE UNA CELULA ANIMAL O UN VIRUS ANIMAL, TAMBIEN SE PRESENTA UN PROCESO PARA PREPARAR EL MISMO, UNA VACUNA VIVA MULTIVALENTE PARA AVES QUE COMPRENDE EL MISMO, Y UN VECTOR PARA LA ADMINISTRACION DE UNA SUBSTANCIA FISIOLOGICAMENTE ACTIVA PARA LAS AVES QUE COMPRENDE EL MISMO.
ES92111588T 1991-07-09 1992-07-08 Virus recombinante de la enfermedad de marek, procedimiento de preparacion de este; y vacuna que lo contiene. Expired - Lifetime ES2195994T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP19570391 1991-07-09

Publications (1)

Publication Number Publication Date
ES2195994T3 true ES2195994T3 (es) 2003-12-16

Family

ID=16345577

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92111588T Expired - Lifetime ES2195994T3 (es) 1991-07-09 1992-07-08 Virus recombinante de la enfermedad de marek, procedimiento de preparacion de este; y vacuna que lo contiene.

Country Status (7)

Country Link
US (1) US5558867A (es)
EP (1) EP0522535B1 (es)
AT (1) ATE237629T1 (es)
AU (1) AU657144B2 (es)
CA (1) CA2073493C (es)
DE (1) DE69233004T2 (es)
ES (1) ES2195994T3 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09508005A (ja) * 1994-01-11 1997-08-19 コーネル リサーチ ファンデーション インコーポレイテッド 潜伏と腫瘍細胞発生の阻害によるマレク病の抑制
WO1995021255A1 (en) * 1994-02-07 1995-08-10 Cornell Research Foundation, Inc. Compositions useful in controlling marek's disease
JPH08116976A (ja) * 1994-10-20 1996-05-14 Chemo Sero Therapeut Res Inst 免疫用核酸調製物およびこれを用いた免疫方法
US6410311B1 (en) * 1997-05-09 2002-06-25 Schering-Plough Veterinary Corporation Recombinant feline herpesvirus comprising a foreign DNA inserted into a region corresponding to a 3.0 kb EcoRI-SalI fragment of a feline herpesvirus genome
US6475770B1 (en) * 1997-06-10 2002-11-05 Pfizer, Inc. Processes for preparation of Marek's Disease using continuous mammalian cell lines
CN1099460C (zh) * 1997-12-26 2003-01-22 扬州大学 鸡马立克氏病病毒基因突变株及其应用
US6410222B1 (en) 1998-12-14 2002-06-25 Juridical Foundation The Chemosero-Therapeutic Research Institute In ovo vaccination of marek's disease type I virus
EP1178111A1 (en) * 2000-08-03 2002-02-06 Lohmann Animal Health GmbH & Co. KG Vaccination against host cell-associated herpesviruses

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2779447B2 (ja) * 1988-03-20 1998-07-23 財団法人阪大微生物病研究会 弱毒マレック病ウイルス・ベクターを用いる組換え遺伝子作成法、及び該ウイルスの組換え体
GB2220941B (en) * 1988-06-24 1991-09-11 Nat Res Dev Fowlpox virus non-essential regions
JP2583115B2 (ja) * 1988-09-10 1997-02-19 財団法人化学及血清療法研究所 組換えマレック病ウイルスおよびその製法
JP3339854B2 (ja) * 1988-09-13 2002-10-28 メリアル ウイルスワクチン
EP0431668B1 (en) * 1989-12-04 1995-02-15 Akzo Nobel N.V. Recombinant herpesvirus of turkeys and live vector vaccines derived thereof
US5231023A (en) * 1990-07-30 1993-07-27 Akzo N.V. Recombinant Marek's disease virus
US6087127A (en) * 1990-08-24 2000-07-11 Board Of Trustees Operating Michigan State University Marek's disease herpesvirus DNA segment encoding glycoproteins, gD, gI and gE
US5138033A (en) * 1990-08-24 1992-08-11 Board Of Trustees Operating Michigan State University Marek's disease herpesvirus glycoproteins GE
JP2607219B2 (ja) * 1991-07-02 1997-05-07 エカ ノーベル アクチェボラーグ 紙の製造方法
US5403581A (en) * 1991-07-12 1995-04-04 Hoffmann-La Roche Inc. Coccidiosis vaccines

Also Published As

Publication number Publication date
EP0522535B1 (en) 2003-04-16
DE69233004D1 (de) 2003-05-22
AU1947892A (en) 1993-01-14
CA2073493C (en) 2003-05-27
AU657144B2 (en) 1995-03-02
US5558867A (en) 1996-09-24
DE69233004T2 (de) 2004-01-22
EP0522535A1 (en) 1993-01-13
CA2073493A1 (en) 1993-01-10
ATE237629T1 (de) 2003-05-15

Similar Documents

Publication Publication Date Title
GB2255777B (en) Indicator cells and recombinant retroviruses for use in the detection of gene sequences
CA2232985C (en) Methods for treating cancers and restenosis with p21
Bateman et al. Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth
Willems et al. Genetic determinants of bovine leukemia virus pathogenesis
Hart et al. Priming of anti-human immunodeficiency virus (HIV) CD8+ cytotoxic T cells in vivo by carrier-free HIV synthetic peptides.
ES2052478T1 (es) Particulas retrovirales no replicantes producidas de forma recombinante empleadas como agentes antivirales e inmunogenos.
WO1991002805A3 (en) Recombinant retroviruses delivering vector constructs to target cells
PT100472A (pt) Sequencias genomicas do virus da hepatite c e composicoes farmaceuticas que as contem, para diagnostico e terapeutica da hepatite c
Temin Retrovirus vectors: promise and reality
Sarzotti et al. Induction of cytotoxic T cell responses in newborn mice by DNA immunization
Rayevskaya et al. Systemic immunity and mucosal immunity are induced against human immunodeficiency virus Gag protein in mice by a new hyperattenuated strain of Listeria monocytogenes
ES2195994T3 (es) Virus recombinante de la enfermedad de marek, procedimiento de preparacion de este; y vacuna que lo contiene.
JPH08509606A (ja) 細胞内感染因子に感染した個体を処置する方法および物質
EP0596032A1 (en) Induction of cytotoxic t-lymphocyte responses
CN108474003A (zh) 包含微小rna识别元件的cmv载体
Noguchi et al. Priming for in vitro and in vivo anti-human T lymphotropic virus type 1 cellular immunity by virus-related protein reconstituted into liposome.
Liao et al. Isolation of chromatin-free RNA polymerase from mammalian cell nuclei
Vrionis et al. Tumor cells expressing the herpes simplex virus—thymidine kinase gene in the treatment of Walker 256 meningeal neoplasia in rats
Wilson Vectors-shuttle vehicles for gene therapy.
WO1994017825A1 (en) Multiple-gene mutants of human immunodeficiency virus (hiv) for vaccine use
DK0777669T3 (da) 4-[2-amino-6-(cyclopropylamino)-9H-purin-yl]-2-cyclopenten-1-methanolsuccinat som antiviralt middel
US6090378A (en) Composition comprising interleukin-2 and thymidine kinase for the treatment of tumors
DE3789525D1 (de) Das F-Protein vom AIDS-Virus enthaltender Impfstoff.
Dwinnell Physiological contraction of double hearts in rabbit embryos
Guichet et al. Are t (X; Y)(p22; q11) translocations in females frequently associated with Madelung deformity?